Top advances of the year: Neoadjuvant therapy in pancreatic cancer
Recent phase 3 trials have generated clinically actionable data that help define neoadjuvant therapy for localized pancreatic ductal adenocarcinoma, while exposing the limitations of anatomic patient selection. Emerging evidence signals that the field is poised to transition toward biology‐driven, response‐adaptive frameworks.
Authors
- Jorge I. Portuondo (ORCID: https://orcid.org/0000-0003-1639-115X)
- Matthew H G Katz (ORCID: https://orcid.org/0000-0003-3870-6968)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Cancer
- Published
- 2026-05-01
- DOI
- https://doi.org/10.1002/cncr.70431
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00